Rushdy has over 18 years of experience as a biomarker hunter with the goal of translating the biomarkers into live saving diagnostics that deliver outcome and save lives. Therefore, it’s quite natural for him to be at the Wyss to help lead and promote the Wyss Diagnostics Accelerator (Wyss DxA). Prior to this he was a neutrino hunter as an experimental physicist and helped solve the long-standing solar neutrino problem which garnered his project director, Art MacDonald, the 2015 Nobel Prize in Physics. But leaving a potentially promising career in physics wasn’t difficult because of his growing desire to help people in need of life saving interventions. To this end, he was able to hone his skills in biomarker discovery and diagnostics as a post-doctoral fellow at Boston University School of Medicine and then at the Broad Institute of MIT and Harvard, where he practiced clinical proteomics and biomarker discovery in all types of diseases for 12 years. In between academic careers he worked in the software industry, built companies and charitable organizations, while never forgetting to dedicate time and resource to serving the underserved, the underprivileged, the disenfranchised. Therefore, his mission at the Wyss is clear, since it’s indeed a privilege to be here and with that privilege comes great responsibility to deliver outcome to those who need it. He joined the Wyss few days before the COVID-19 pandemic shutdown in March of 2020 and was able to jump into the worldwide battle and effectively lead the direct-to-consumer (DTC) diagnostics working group for the Mass General Brigham Center for COVID Innovation (MGBCCI). With the successful launch of the Brigham-Wyss DxA and the Industrial Participant Program (IPP) in 2021, the task of accelerating the delivery of diagnostics is coming into focus. Rushdy received his PhD from Brown University.